Musk quietly puts brakes on plans for new ‘America Party,' WSJ reports
Musk, without commenting further on the report, said in an X post: 'Nothing @WSJ says should ever be thought of as true'.
Musk, the world's richest man, unveiled the 'America Party' in July after a public dispute with U.S. President Donald Trump on the tax cut and spending bill.
Elon Musk says new U.S. political party formed, named 'America Party'
Tesla slides as Musk's 'America Party' reignites investor angst
He has recently been focused in part on maintaining ties with Vice President JD Vance, the paper said, and has acknowledged to associates that forming a political party would damage his relationship with Vance.
Musk and his associates have told people close to Vance that the billionaire is considering using some of his financial resources to back Vance if he decides to run for president in 2028, the paper said.
The CEO of Tesla and SpaceX spent nearly US$300-million in 2024 to help Trump and other Republicans get elected, exerting enormous influence in the first few weeks of Trump's term as head of newly created efficiency department DOGE.
Reuters could not immediately verify the Journal report. Tesla and the White House did not immediately respond to a Reuters request for comment outside regular business hours.
Vance, who had called for a truce following Musk's all-public feud with Trump, reaffirmed his position this month and said he had asked Musk to return to the Republican fold.
Tesla shares are down more than 18 per cent this year after it posted in July its worst quarterly sales decline in more than a decade and profit that missed Wall Street targets, though its profit margin was better than many had feared.
Musk also warned of 'a few rough quarters' after the end of support for electric vehicles by the Trump administration.
Investors worry whether he will be able to devote enough time and attention to Tesla after locking horns with Trump over his ambitions for a new political party.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Toronto Star
18 minutes ago
- Toronto Star
The Latest: California Democrats will vote on a new congressional map to counter Texas
The national redistricting battle enters its next phase with California Democrats scheduled Thursday to pass a new congressional map for voters to consider in November that would create five more winnable seats for their party, a direct counter to the GOP Texas House members imposing a new map on their state's voters at the urging of President Donald Trump. California Gov. Gavin Newsom has engineered the high-risk strategy in response to Trump's brinkmanship in Texas, where passage by the Republican-controlled state Senate and signature by Republican Gov. Greg Abbott are now all that's needed to make the maps official. California by contrast has an independent commission and only a voter-approved ballot measure can override the current map.
Globe and Mail
18 minutes ago
- Globe and Mail
AI Fatigue Hits Tech Biggies: Inverse ETFs in Focus
Short sellers are wagering against top AI stocks currently, which has earned them billions. On Wednesday, the Nasdaq Composite fell 0.7%, capping a two-day decline of 1.5% as concerns about the sustainability of the AI boom made the rounds. According to data from S3 Partners, short sellers amassed $5.6 billion on wagers against AI-linked companies in just two trading sessions. Big Tech Takes a Hit Among the Magnificent Seven, Meta META has been the hardest hit, down 4% over the past five sessions. NVIDIA NVDA slipped 3.8%, while Microsoft MSFT and Apple AAPL fell nearly 3% each. Alphabet GOOG also fell about 1%. Short bets against these five giants alone led to $2.8 billion in profits for investors over the past two days. Sharp Losses Outside the Tech Biggies Beyond Big Tech, losses were steeper. Advanced Micro Devices AMD slid more than 10% in the last week, while Broadcom AVGO and Micron MU each fell over 5%. AI data center operator CoreWeave CRWV — seen as an AI 'pure play' — nosedived 24% in the same period. Meta and Palantir Under Pressure Meta has made huge investments in AI. Despite this, short sellers increased positions worth $4.7 billion over the past week, reaping $1.1 billion in profits in just two days. Meanwhile, Palantir PLTR, which had surged more than 150% since April, has now fallen over 15% in its longest losing streak since March. Investors shorting Palantir have gained more than $1 billion. AI Bubble Speculations The recent downturn has been fueled by shifting sentiment. On Monday, researchers for MIT's Project NANDA released a report saying 95% of companies it studied are getting no return on AI. The findings of the report were first detailed by Fortune, as quoted on Yahoo Finance. Moreover, OpenAI CEO Sam Altman recently indicated that the industry may be in a bubble reminiscent of the dot-com crash. DA Davidson analyst Gil Luria compared the selloff to a pendulum swing, indicating that AI still has 'limited applications' outside of chatbots and search. This has tempered enthusiasm among investors, as quoted on Yahoo Finance. Any Silver Lining? AI bulls like Wedbush's Dan Ives remain optimistic. He described the current pullback as temporary and said AI will continue to drive markets higher. He added that 'the tech bull cycle will be well intact at least for another 2-3 years given the trillions being spent on AI.' Inverse ETFs in Focus Still, if you are of the view that the AI stock valuations are too stretched, you can play inverse tech-based exchange-traded funds (ETFs) at the current level. These ETFs include the likes of ProShares UltraPro Short QQQ SQQQ, Direxion Daily Technology Bear 3X Shares TECS, MicroSectors Solactive FANG & Innovation -3X Inverse Leveraged ETN BERZ and ProShares UltraShort QQQ QID, which have gained materially. SQQQ, TECS, BERZ and QID gained 1.8%, 1.8%, 4% and 1.2%, respectively, on Aug. 21, 2025. Boost Your Portfolio with Our Top ETF Insights Zacks' exclusive Fund Newsletter delivers actionable information, top news and analysis, as well as top-performing ETFs, straight to your inbox every week. Don't miss out on this valuable resource. It's free! Get it now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Alphabet Inc. (GOOG): Free Stock Analysis Report Apple Inc. (AAPL): Free Stock Analysis Report Advanced Micro Devices, Inc. (AMD): Free Stock Analysis Report Microsoft Corporation (MSFT): Free Stock Analysis Report Micron Technology, Inc. (MU): Free Stock Analysis Report NVIDIA Corporation (NVDA): Free Stock Analysis Report Broadcom Inc. (AVGO): Free Stock Analysis Report ProShares UltraPro Short QQQ (SQQQ): ETF Research Reports Palantir Technologies Inc. (PLTR): Free Stock Analysis Report Meta Platforms, Inc. (META): Free Stock Analysis Report CoreWeave Inc. (CRWV): Free Stock Analysis Report
Globe and Mail
18 minutes ago
- Globe and Mail
Tvardi Therapeutics to Participate in the Cantor Global Healthcare Conference
Tvardi Therapeutics, Inc. ('Tvardi') (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that the Company's Management will participate in a fireside chat at the Cantor Global Healthcare Conference on Thursday, September 4, 2025 at 2:10 PM EDT and participate in one-on-one investor meetings. The webcast of the fireside chat will be accessible on the Tvardi Investors' website. A replay of the webcast will be available for approximately 90 days following the conference. About Tvardi Therapeutics Tvardi is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. The company is conducting Phase 2 clinical trials in fibrosis-driven diseases with high unmet need: idiopathic pulmonary fibrosis ( NCT05671835) and hepatocellular carcinoma ( NCT05440708). To learn more, please visit or follow us on LinkedIn and X (Twitter).
